Clinical Trials Logo

Recurrence clinical trials

View clinical trials related to Recurrence.

Filter by:

NCT ID: NCT00057577 Completed - Depression Clinical Trials

Prevention of Recurrence in Depression With Drugs and CT

CPT3
Start date: October 2002
Phase: Phase 4
Study type: Interventional

This study will determine whether the addition of Cognitive Therapy (CT) to antidepressant medication (ADM) enhances treatment for depression. This study will also test whether the addition of CT to ADM will prevent recurrences of depression after therapy is over.

NCT ID: NCT00046020 Completed - Clinical trials for Depressive Disorder, Major

Study Evaluating Venlafaxine ER in Recurrent Depression

Start date: August 2000
Phase: Phase 4
Study type: Interventional

The purpose of this study is to review the long-term comparative efficacy of venlafaxine ER in achieving and sustaining remission (wellness) in patients with recurrent major depression

NCT ID: NCT00029185 Completed - Recurrence Clinical Trials

Study of Dehydrex in Patients With Corneal Erosion

Start date: September 2001
Phase: N/A
Study type: Interventional

This is a compassionate-use treatment study to provide Dehydrex to patients with corneal erosion syndrome who have previously used Dehydrex.

NCT ID: NCT00020202 Completed - Clinical trials for Stage IV Non-small Cell Lung Cancer

FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer

Start date: June 2000
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of FR901228 in treating patients who have refractory or progressive small cell lung cancer or non-small cell lung cancer.

NCT ID: NCT00019760 Completed - Liver Metastases Clinical Trials

Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver

Start date: April 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of melphalan given as an isolated hepatic perfusion followed by chemotherapy infused into the liver in patients who have unresectable colorectal cancer that is metastatic to the liver.

NCT ID: NCT00019448 Completed - Stage IV Melanoma Clinical Trials

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Start date: September 1998
Phase: Phase 2
Study type: Interventional

RATIONALE: Vaccines made from DNA may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. Combining vaccine therapy and interleukin-2 may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy with or without interleukin-2 in treating patients with metastatic melanoma that has not responded to previous treatment.

NCT ID: NCT00019396 Completed - Stage IV Melanoma Clinical Trials

flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer

Start date: February 1998
Phase: Phase 2
Study type: Interventional

RATIONALE: The drug flt3L may stimulate a person's immune system and help to kill tumor cells. Vaccines made from melanoma cells may make the body build an immune response to and kill their tumor cells. PURPOSE: Phase II trial to study the effectiveness of flt3L with or without vaccine therapy in treating patients with metastatic melanoma or renal cell cancer.

NCT ID: NCT00019006 Completed - Clinical trials for Recurrent Rectal Cancer

Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer

Start date: March 1995
Phase: Phase 1
Study type: Interventional

RATIONALE: Vaccines made from mutated ras peptides may make the body build an immune response to and kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer.